foxo4-dri senolytic or senomorphic Class II senolytics inhibit survival pathways elicited by senescent The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Targeting Cellular Senescence in Aging and Age Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies FOXO4 DRI Dosing: 1mg Senolytic Protocol (2026) Buy FOXO4 DRI (10mg) (Proxofim) 99% Purity USA Made Peptide FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Targeting cellular senescence with senotherapeutics: senolytics and senomorphics Zhang 2023 The FEBS Journal Wiley Online Library
Pay in 4 interest-free payments of $5.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7




